Zentalis Pharmaceuticals reported a net loss of $48.3 million for the first quarter of 2025, a significant decrease from the net income of $10.1 million in the same period last year, primarily due to the absence of license revenue and higher operating expenses including restructuring costs. The company ended the quarter with $332.5 million in cash, cash equivalents, and marketable securities, which is expected to fund operations into late 2027. Key operational progress included the first patient dosed in Part 2a of the Phase 2 DENALI clinical trial for azenosertib in patients with Cyclin E1+ platinum-resistant ovarian cancer.